phenylpropyl carbamimidothioate hydrobromide | 105444-69-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: phenylpropyl carbamimidothioate hydrobromide
• 英文别名: S-(3-phenyl-propyl)-isothiourea; hydrobromide；S-(3-Phenyl-propyl)-isothioharnstoff; Hydrobromid；2-(3-phenyl-propyl)-isothiourea hydrobromide；[(3-Phenylpropyl)sulfanyl]methanimidamide hydrobromide；3-phenylpropyl carbamimidothioate;hydrobromide
• CAS: 105444-69-7
• 化学式: BrH*C₁₀H₁₄N₂S
• 分子量: 275.212
• InChiKey: AVFKYLRCDFIXNU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.82
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  75.2
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  phenylpropyl carbamimidothioate hydrobromide 在 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 反应 0.5h， 生成
  参考文献：
  名称：

  由脂肪族亲电试剂合成二氟甲基和氘标记的二氟甲基硫醚

  摘要：

  描述了烷基亲电试剂与硫脲和溴代二氟甲基膦酸二乙酯的一锅二氟甲基硫醇化。不含过渡金属的方法，容易获得的试剂和温和的条件为合成二氟甲基硫醚提供了一种实用的方法。通过将“ H”源更改为最常用的“ D”源CD 3 OD和D 2 O，此策略能够以高收率和高D掺入量高效合成SCF 2 D取代分子。

  DOI：

  10.1039/c9cc09709k
• 作为产物：
  描述：

  3-苯丙醇 、 硫脲 在 氢溴酸 作用下， 生成 phenylpropyl carbamimidothioate hydrobromide
  参考文献：
  名称：

  El-Hewehi; Saleh, Journal fur praktische Chemie (Leipzig 1954), 1959, vol. <4> 7, p. 286,291

  摘要：

  DOI：

文献信息

• Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors
  申请人：Malherbe Pari

  公开号：US20050197337A1

  公开（公告）日：2005-09-08

  The present invention relates to compounds of formula whereinX is —S— or —NH—; R 3 /R 4 together with the N-atom to which they are attached form a non aromatic 5, 6 or 7 membered ring, which optionally contains in addition to the N-atom one additional heteroatom selected from the group consisting of O, S and N, and wherein the ring is optionally substituted by hydroxy, lower alkyl, lower alkoxy, —NR 2 , —CONR 2 , —CO-lower alkyl or benzyl; or R 3 /R 4 form together with the N-atom to which they are attached a heterocyclic ring system, containing two or three rings and which optionally contains one or two additional heteroatoms selected from the group consisting of N and O and which has no more than 20 carbon atoms; and R, R 1 , R 2 , and R 5 are as defined herein and to pharmaceutically suitable acid addition salts thereof. It has been found that the compounds of the invention are active on the GABA B receptor and therefore are useful for the treatment of anxiety, depression, epilepsy, schizophrenia, cognitive disorders, spasticity and skeletal muscle rigidity, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy, neuropathic pain and craving associated with cocaine and nicotine, psychosis, panic disorder, posttraumatic stress disorders and gastro-intestinal disorders.

  本发明涉及具有以下公式的化合物：其中X是-S-或-NH-；R3/R4与它们所连接的N原子一起形成一个非芳香性的5、6或7元环，该环除了N原子外，还可以选择性地包含一个额外的杂原子，该杂原子选自O、S和N的组中，并且环可以选择性地被羟基、低级烷基、低级烷氧基、-NR2、-CONR2、-CO-低级烷基或苄基取代；或者R3/R4与它们所连接的N原子一起形成一个含有两个或三个环的杂环体系，该体系可以选择性地包含一个或两个额外的杂原子，这些杂原子选自N和O的组中，并且含有的碳原子数不超过20个；以及R、R1、R2和R5如本文所述，以及药用适当的酸加成盐。已经发现，本发明的化合物对GABAB受体具有活性，因此可用于治疗焦虑、抑郁、癫痫、精神分裂症、认知障碍、痉挛和骨骼肌僵直、脊髓损伤、多发性硬化症、肌萎缩侧索硬化症、脑瘫、神经性疼痛以及与可卡因和尼古丁相关的渴望、精神疾病、恐慌症、创伤后应激障碍和胃肠功能障碍。
• [EN] 4- (SULFANYL-PYRIMIDIN-4-YLMETHYL) -MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS GABA RECEPTOR LIGANDS FOR THE TREATMENT OF ANXIETY, DEPRESSION AND EPILEPSY<br/>[FR] DERIVES DE 4-(SULFANYL-PYRIMIDINE-4-YLMETHYLE)-MORPHOLINE ET COMPOSES ASSOCIES UTILISES EN TANT QUE LIGANDS RECEPTEURS GABA DANS LE TRAITEMENT DE L'ANXIETE, DE LA DEPRESSION ET DE L'EPILEPSIE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005094828A1

  公开（公告）日：2005-10-13

  The present invention relates to compounds of Formula (I) wherein X is -S- or -NH-; R1 is alkyl, alkenyl, arylalkyl, arylalkenyl or aryl-O-alkyl, wherein the aryl groups are optionally substituted by one or more substituents, selected from the group consisting of lower alkyl, lower alkoxy, halogen or lower halogen-alkyl; R2 is hydrogen, lower alkyl or cycloalkyl; R3/R4 may form together with the N-atom to which they are attached a non aromatic5, 6 or 7 membered ring, which may contain in addition to the N-atom one additional heteroatom selected from the group consisting of O, S or N, and wherein the ring is optionally substituted by hydroxy, lower alkyl, lower alkoxy, -NR2, -CONR2, -CO-lower alkyl or benzyl; or may form together with the N-atom to which they are attached a heterocyclic ring system, containing at least two rings and which may contain one or two additional heretoatoms, selected from the group consisting of N or O; R is hydrogen or lower alkyl; R5 is hydrogen or lower alkyl; and to pharmaceutically suitable acid addition salts thereof. It has been found that the compounds are active on the GABAB receptor and therefore useful for the treatment of anxiety, depression, epilepsy, schizophrenia, cognitive disorders, spasticity and skeletal muscle rigidity, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy, neuropathic pain and craving associated with cocaine and nicotine, psychosis, panic disorder, posttraumatic stress disorders or gastro-intestinal disorders.

  本发明涉及公式(I)所示的化合物，其中X是-S-或-NH-；R1是烷基、烯基、芳烷基、芳烯基或芳基-O-烷基，其中芳基可被选自低烷基、低烷氧基、卤素或低卤代烷基的一个或多个取代基所取代；R2是氢、低烷基或环烷基；R3/R4可与它们所连接的N原子共同形成一个非芳香性的5、6或7元环，该环除了N原子外，还可包含一个选自O、S或N的附加杂原子，并且该环可被羟基、低烷基、低烷氧基、-NR2、-CONR2、-CO-低烷基或苄基所取代；或者可与它们所连接的N原子共同形成一个含有至少两个环的杂环体系，该体系可包含一个或两个选自N或O的附加杂原子；R是氢或低烷基；R5是氢或低烷基；以及涉及药用适宜的酸加成盐。已经发现，这些化合物对GABAB受体具有活性，因此可用于治疗焦虑、抑郁、癫痫、精神分裂症、认知障碍、痉挛和骨骼肌僵直、脊髓损伤、多发性硬化症、肌萎缩性侧索硬化症、脑瘫、神经性疼痛以及与可卡因和尼古丁相关的渴望、精神疾病、恐慌症、创伤后应激障碍或胃肠功能紊乱。
• Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB₁R Inverse Agonist/Inducible Nitric Oxide Synthase (iNOS) Inhibitors for the Treatment of Liver Fibrosis
  作者：Malliga R. Iyer、Resat Cinar、Alexis Katz、Michael Gao、Katalin Erdelyi、Tony Jourdan、Nathan J. Coffey、Pal Pacher、George Kunos

  DOI：10.1021/acs.jmedchem.6b01504

  日期：2017.2.9

  We report the design, synthesis, and structure–activity relationships of novel dual-target compounds with antagonist/inverse agonist activity at cannabinoid receptor type 1 (CB1R) and inhibitory effect on inducible nitric oxide synthase (iNOS). A series of 3,4-diarylpyrazolinecarboximidamides were synthesized and evaluated in CB1 receptor (CB1R) binding assays and iNOS activity assays. The novel compounds

  我们报告了新型双靶化合物的设计，合成和结构活性关系，该化合物在1型大麻素受体（CB 1 R）上具有拮抗/反向激动剂活性，并且对诱导型一氧化氮合酶（iNOS）具有抑制作用。合成了一系列3,4-二芳基吡唑啉羧酰亚胺衍生物，并通过CB 1受体（CB 1 R）结合测定和iNOS活性测定进行了评估。被设计为具有有限的脑渗透能力的新型化合物引发了有效的体外CB 1 R拮抗剂活性和iNOS抑制活性。一些关键化合物显示出高的CB 1 R结合亲和力。化合物7在iNOS抑制和CB 1 R拮抗作用介导的纤维化动物模型中，已证实了有效的体内药理活性，例如通过CB 1 Rs拮抗作用介导的食物摄取减少和抗纤维化作用。
• Inhibition of monoamine oxidase by 8-[(phenylethyl)sulfanyl]caffeine analogues
  作者：Samantha Mostert、Wayne Mentz、Anél Petzer、Jacobus J. Bergh、Jacobus P. Petzer

  DOI：10.1016/j.bmc.2012.10.005

  日期：2012.12

  In a previous study we have investigated the monoamine oxidase (MAO) inhibitory properties of a series of 8-sulfanylcaffeine analogues. Among the compounds studied, 8-[(phenylethyl) sulfanyl] caffeine (IC50 = 0.223 mu M) was found to be a particularly potent inhibitor of the type B MAO isoform. In an attempt to discover potent MAO inhibitors and to further examine the structure-activity relationships (SAR) of MAO inhibition by 8-sulfanylcaffeine analogues, in the present study a series of 8-[(phenylethyl)sulfanyl] caffeine analogues were synthesized and evaluated as inhibitors of human MAO-A and -B. The results document that substitution on C3 and C4 of the phenyl ring with alkyl groups and halogens yields 8-[( phenylethyl) sulfanyl] caffeine analogues which are potent and selective MAO-B inhibitors with IC50 values ranging from 0.017 to 0.125 mu M. The MAO inhibitory properties of a series of 8-sulfinylcaffeine analogues were also examined. The results show that, compared to the corresponding 8-sulfanylcaffeine analogues, the 8-sulfinylcaffeins are weaker MAO-B inhibitors. Both the 8-sulfanylcaffeine and 8-sulfinylcaffeine analogues were found to be weak MAO-A inhibitors. This study also reports the MAO inhibition properties of selected 8-[(phenylpropyl) sulfanyl] caffeine analogues. (C) 2012 Elsevier Ltd. All rights reserved.
• Synthesis of <i>N</i>-Glyoxyl Prolyl and Pipecolyl Amides and Thioesters and Evaluation of Their In Vitro and In Vivo Nerve Regenerative Effects
  作者：Gregory S. Hamilton、Yong-Qian Wu、David C. Limburg、Douglas E. Wilkinson、Mark J. Vaal、Jia-He Li、Christine Thomas、Wei Huang、Hansjorg Sauer、Douglas T. Ross、Raj Soni、Yi Chen、Hongshi Guo、Pamela Howorth、Heather Valentine、Shi Liang、Dawn Spicer、Mike Fuller、Joseph P. Steiner

  DOI：10.1021/jm010556c

  日期：2002.8.1

  The recent discovery that small molecule ligands for the peptidyl-prolyl isomerase (PPIase) FKBP12 possess powerful neuroprotective and neuroregenerative properties in vitro and in vivo suggests therapeutic utility for such compounds in neurodegenerative disease. The neurotrophic effects of these compounds are independent of the immunosuppressive pathways by which drugs such as FK506 and rapamycin operate. Previous work by ourselves and other groups exploring the structure-activity relationships (SAR) of small molecules that mimic only the FKBP binding domain portion of FK506 has focused on esters of proline and pipecolic acid. We have explored amide and thioester analogues of these earlier structures and found that they too are extremely potent in promoting recovery of lesioned dopaminergic pathways in a mouse model of Parkinson's disease. Several compounds were shown to be highly effective upon oral administration after lesioning of the dopaminergic pathway, providing further evidence of the potential clinical utility of a variety of structural classes of FKBP12 ligands.